Hematologic Malignancies


Share

Program Content

Activities

  • ASC4FIRST
    ASC4FIRST: Phase III Trial of Asciminib vs Investigator-Selected TKIs in Newly Diagnosed CML
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2024

    Expires: June 02, 2025

  • DREAMM-8
    DREAMM-8: Phase III Trial of Belantamab Mafodotin + Pomalidomide/Dexamethasone (BPd) vs Pomalidomide + Bortezomib/Dexamethasone (PVd) in RRMM
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2024

    Expires: June 03, 2025

  • Integrated Palliative Care in AML/MDS
    Integration of Palliative and Oncology Care for Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Treated With Nonintensive Therapy
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2024

    Expires: June 03, 2025

  • MANIFEST 2
    MANIFEST-2 Update: Phase III Trial of Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2024

    Expires: June 04, 2025

  • Pirtobrutinib Prior to CAR T Therapy
    Pirtobrutinib Prior to Bispecific Anti-CD20/CD19 CAR T-Cell Therapy in Patients With Relapsed/Refractory Lymphoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2024

    Expires: June 04, 2025

  • DEB: Tucidinostat + RCHOP in DLBCL
    Phase III DEB Trial: Interim Analysis of Tucidinostat + R-CHOP vs R-CHOP Alone as 1L Tx in MYC and BCL2 Double-Expressing DLBCL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2024

    Expires: June 05, 2025

  • ECHELON-3
    ECHELON-3: Phase III, Placebo-Controlled Trial of Brentuximab Vedotin in Combination With Lenalidomide and Rituximab in R/R DLBCL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2024

    Expires: June 05, 2025

  • FELIX: Obe Cel in Adult B ALL
    FELIX: Phase Ib/II Study of Obecabtagene Autoleucel in Adults With Relapsed/Refractory B-Cell ALL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2024

    Expires: June 05, 2025

  • Cytopenias and MNs After CAR T Therapy
    Cytopenias and Myeloid Neoplasms After CAR T-Cell Therapies
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2024

    Expires: June 05, 2025

  • IMROZ
    IMROZ: Phase III Study of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible, Newly Diagnosed MM
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2024

    Expires: June 05, 2025

  • BENEFIT IsaVRd vs IsaRd
    BENEFIT/IFM 2020-05: Phase III Trial of Isa-VRd vs Isa-Rd in Patients With Transplant-Ineligible NDMM
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2024

    Expires: June 06, 2025

  • PERSEUS MRD Analysis
    Phase III PERSEUS: MRD Analysis of VRd ± Daratumumab in Newly Diagnosed Multiple Myeloma Eligible for ASCT
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2024

    Expires: June 06, 2025

  • ASCO 2024: Leukemias
    Conference to Clinic: Leukemias
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 18, 2024

    Expires: June 17, 2025

  • Lymphomas
    Conference to Clinic: Lymphomas
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 20, 2024

    Expires: June 19, 2025

  • Multiple Myeloma
    Conference to Clinic: Multiple Myeloma
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 20, 2024

    Expires: June 19, 2025

  • ASCO 2024 Heme Malig WC
    Conference to Clinic: Hematologic Malignancies
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 02, 2024

    Expires: January 01, 2025

  • ASCO 2024: Hematologic Malignancies
    Key Studies in Hematologic Malignancies: Independent Conference Coverage of the 2024 ASCO Annual Meeting
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 16, 2024

    Expires: February 15, 2025

Faculty

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematology Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Associate Chair for Research, Department of Medicine
Mayo Clinic
Rochester, Minnesota

cover img faculity

Jeffrey P. Sharman, MD

Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from GSK, Lilly, Novartis Pharmaceuticals Corporation, and Sanofi.

GSK

Lilly

Novartis Pharmaceuticals Corporation

Sanofi